Number of slides
-
CURRENT: STARMER BATTLES CALLS TO RESIGN OVER MANDELSON VETTING
Starmer battles calls to resign over Mandelson vettingConservatives refuse to accept prime minister’s move to shift blame by sacking top Foreign Office official17. april 2026 -
CURRENT: DATA CENTRE DELAYS THREATEN TO CHOKE AI EXPANSION
Data centre delays threaten to choke AI expansionAlmost 40% of such builds in US risk hold-ups, including projects tied to Microsoft and OpenAI17. april 2026 -
CURRENT: WELCOME TO THE AGE OF HOARDING
Welcome to the age of hoardingAs global economic uncertainty mounts, stockpiling is back17. april 2026 -
CURRENT: TRUMP'S LEBANON CEASEFIRE TAKES ISRAEL BY SURPRISE
Trump's Lebanon ceasefire takes Israel by surpriseFew Israelis see this truce as a way out of the conflict with Hezbollah, the BBC's Lucy Williamson writes.16. april 2026 -
CURRENT: SINGER D4VD ARRESTED ON SUSPICION OF MURDERING TEENAGE GIRL
Singer D4vd arrested on suspicion of murdering teenage girlThe remains of 14-year-old Celeste Rivas Hernandez were found in the singer's car last year.17. april 2026 -
CURRENT: FINANCE MINISTERS AND TOP BANKERS RAISE SERIOUS CONCERNS ABOUT MYTHOS AI MODEL
Finance ministers and top bankers raise serious concerns about Mythos AI modelExperts say Mythos potentially has an unprecedented ability to identify and exploit cybersecurity weaknesses.17. april 2026 -
CURRENT: LEO PHARMA FÅR GODKENDT PSORIASISMIDDEL I KINA
Leo Pharma får godkendt psoriasismiddel i KinaDermatologiselskabet vil lancere Enstilar senere i år. Det sker efter ti år uden lanceringer på det kinesiske marked, hvor Leo Pharma har oplevet modvind det seneste år.
Medicinal & Biotek17. april 2026 -
CURRENT: NOVO NORDISKS WEGOVY-TABLET FORTSÆTTER FREM
Novo Nordisks Wegovy-tablet fortsætter fremDet er, selvom Eli Lillys konkurrerende vægttabstablet er lanceret i USA.
Resultater17. april 2026 -
CURRENT: "INGEN FREE RIDE": LIF-CHEF KLAR TIL, AT INDUSTRIEN DELER RISIKOEN FOR NYE LÆGEMIDLER
"Ingen free ride": Lif-chef klar til, at industrien deler risikoen for nye lægemidlerLif vil bidrage med løsningsforslag, men kræver også større villighed til at investere i innovation og forandringer i Medicinrådets model. Industrien er klar til risikodeling, hvis rammerne ændres.
Medicinal & Biotek17. april 2026